Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26229022 | 0.94 | MAPT (0.39) | MAPTTSHRFKBP1ASMN1; SMN2KDM4E | |
| SCHEMBL30118627 | 0.94 | PDE10A (0.34) | MAPTSMN1; SMN2HPGDALDH1A1HTT | |
| SCHEMBL23976419 | 0.94 | PDE10A (0.34) | MAPTSMN1; SMN2HPGDALDH1A1HTT | |
| SCHEMBL30118621 | 0.93 | PDE10A (0.34) | MAPTSMN1; SMN2HPGDALDH1A1HTT | |
| SCHEMBL23976726 | 0.93 | PDE10A (0.34) | MAPTSMN1; SMN2HPGDALDH1A1HTT | |
| SCHEMBL23976483 | 0.90 | ALDH1A1 (0.41) | MAPTTSHRFKBP1ASMN1; SMN2KDM4E | |
| SCHEMBL23976390 | 0.89 | PDE10A (0.33) | HPGDPDE10A | |
| SCHEMBL26229044 | 0.88 | SYK (0.36) | MAPTSMN1; SMN2HPGDALDH1A1HTT | |
| SCHEMBL26229002 | 0.87 | SYK (0.35) | MAPTSMN1; SMN2HPGDALDH1A1HTT | |
| SCHEMBL30225330 | 0.86 | SPR (0.36) | MAPTSMN1; SMN2KDM4EPDE10APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222363-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | MAPT 4261/4885TSHR 2368/4885FKBP1A 1284/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | MAPT 4441/4885TSHR 2165/4885FKBP1A 311/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | MAPT 4441/4885TSHR 2165/4885FKBP1A 311/4885 |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | MAPT 4441/4885TSHR 2165/4885FKBP1A 311/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | MAPT 4441/4885TSHR 2165/4885FKBP1A 311/4885 |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | MAPT 4441/4885TSHR 2165/4885FKBP1A 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.